Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
PT-141
Also known as: Bremelanotide, Vyleesi
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Risk Level
Medium RiskDifficulty
Beginner| CAS Number | 189691-06-3 |
| Molecular Formula | C50H68N14O10 |
| Class | Peptide |
| Category | Well-Known Peptides |
Mechanism of Action
Bremelanotide is a non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R, with its pro-sexual effects primarily mediated through MC4R activation in the hypothalamus. MC4R activation in the medial preoptic area and paraventricular nucleus modulates dopaminergic and oxytocinergic pathways involved in sexual arousal and desire. It is a metabolite of Melanotan II but lacks significant tanning effects at therapeutic doses.
Dosing Research
The FDA-approved dose is 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity. No more than one dose should be given within 24 hours, and no more than 8 doses per month is recommended. Research doses have ranged from 0.5-2 mg.
Side Effects & Risks
Nausea is the most common side effect, occurring in approximately 40% of patients and usually resolving within 2 hours. Flushing, headache, and injection site reactions are also common. Transient increases in blood pressure have been observed, making it contraindicated in uncontrolled hypertension. Focal hyperpigmentation may occur with repeated use.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
MK-677
PeptideMK-677 is an orally active, non-peptide growth hormone secretagogue that mimics the action of ghrelin at the GHS-R1a receptor. It significantly increases growth hormone and IGF-1 levels without affecting cortisol. Multiple human clinical trials have demonstrated its efficacy in improving body composition, sleep quality, and bone density.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.